COVID19 biomarkers: What did we learn from systematic reviews?
S Semiz - Frontiers in cellular and infection microbiology, 2022 - frontiersin.org
The coronavirus disease 2019 (COVID19) pandemic continues to represent a substantial
public health concern. It can rapidly progress to severe disease, with poor prognosis and a …
public health concern. It can rapidly progress to severe disease, with poor prognosis and a …
[HTML][HTML] Active prescription of low-dose aspirin during or prior to hospitalization and mortality in COVID-19: A systematic review and meta-analysis of adjusted effect …
Background This study aimed to investigate whether the active prescription of low-dose
aspirin during or prior to hospitalization affects mortality in patients with coronavirus disease …
aspirin during or prior to hospitalization affects mortality in patients with coronavirus disease …
Does aspirin have an effect on risk of death in patients with COVID-19? A meta-analysis
Purpose The coronavirus disease 2019 (COVID-19) pandemic has shown unprecedented
impact world-wide since the eruption in late 2019. Importantly, emerging reports suggest an …
impact world-wide since the eruption in late 2019. Importantly, emerging reports suggest an …
[HTML][HTML] The use of Janus Kinase inhibitors in hospitalized patients with COVID-19: Systematic review and meta-analysis
Background The evidence of using JAK inhibitors among hospitalized patients with COVID-
19 is conflicting. The systematic review and meta-analysis aimed to address the efficacy of …
19 is conflicting. The systematic review and meta-analysis aimed to address the efficacy of …
[HTML][HTML] Endotheliopathy marked by high von Willebrand factor (vWF) antigen in COVID-19 is associated with poor outcome: a systematic review and meta-analysis
Background This systematic review and meta-analysis aimed to compare the levels of von
Willebrand Factor (vWF) antigen in patients with coronavirus disease 2019 (COVID-19) with …
Willebrand Factor (vWF) antigen in patients with coronavirus disease 2019 (COVID-19) with …
Dipeptidyl peptidase-4 (DPP-IV) inhibitor was associated with mortality reduction in COVID-19—A systematic review and meta-analysis
AFMZ Zein, WM Raffaello - Primary care diabetes, 2022 - Elsevier
Introduction This systematic review and meta-analysis aimed to synthesize the latest
evidence on the effect of dipeptidyl peptidase-4 (DPP-IV) inhibitor in patients with COVID-19 …
evidence on the effect of dipeptidyl peptidase-4 (DPP-IV) inhibitor in patients with COVID-19 …
SARS-CoV-2 infection: differences in hematological parameters between adults and children
L Liu, J She, Y Bai, W Liu - International journal of general medicine, 2021 - Taylor & Francis
Since December 2019, corona virus disease 2019 (COVID-19) caused by severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2) has become a global pandemic, posing …
respiratory syndrome coronavirus 2 (SARS-CoV-2) has become a global pandemic, posing …
[PDF][PDF] Prevalence of dengue hemorrhagic fever in Bali from 2015 to 2020 and during the COVID-19 pandemic.
I Mertha Adnyana, FS Salsabila Azhari… - Periodic …, 2022 - e-journal.unair.ac.id
Background: Dengue hemorrhagic fever cases increased significantly during the COVID-19
pandemic phase. Purpose: This study defines, describes, and evaluates the dengue …
pandemic phase. Purpose: This study defines, describes, and evaluates the dengue …
Inflammation and venous thromboembolism in hospitalized patients with COVID-19
A Liontos, D Biros, R Matzaras, KH Tsarapatsani… - Diagnostics, 2023 - mdpi.com
Background: A link between inflammation and venous thromboembolism (VTE) in COVID-19
disease has been suggested pathophysiologically and clinically. The aim of this study was …
disease has been suggested pathophysiologically and clinically. The aim of this study was …
Accuracy of routine laboratory tests to predict mortality and deterioration to severe or critical COVID‐19 in people with SARS‐CoV‐2
L De Rop, DAG Bos, I Stegeman… - Cochrane Database …, 2024 - cochranelibrary.com
Background Identifying patients with COVID‐19 disease who will deteriorate can be useful
to assess whether they should receive intensive care, or whether they can be treated in a …
to assess whether they should receive intensive care, or whether they can be treated in a …